Trials / Recruiting
RecruitingNCT06823609
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
A Phase I Clinical Study to Evaluate Safety, Tolerability, PK Characteristic and Preliminary Efficacy of QLS-1304 in Patients With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS1304 tablet | QLS1304 monotherapy dose escalation and expansion |
Timeline
- Start date
- 2025-03-06
- Primary completion
- 2026-11-01
- Completion
- 2027-12-01
- First posted
- 2025-02-12
- Last updated
- 2026-01-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06823609. Inclusion in this directory is not an endorsement.